Abstract:
A photocurable coating composition includes 50 to 150 parts by weight of a urethane acrylate oligomer having a number average molecular weight of 1300 to 1700 g/mol and 9 functional groups, 50 to 150 parts by weight of an acrylate monomer, 10 to 15 parts by weight of a photoinitiator, and 1 to 3 parts by weight of a surfactant.
Abstract:
A photocurable coating composition includes 50 to 150 parts by weight of a urethane acrylate oligomer having a number average molecular weight of 1300 to 1700 g/mol and 9 functional groups, 50 to 150 parts by weight of an acrylate monomer, 10 to 15 parts by weight of a photoinitiator, and 1 to 3 parts by weight of a surfactant.
Abstract:
A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
Abstract:
An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.
Abstract:
A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.
Abstract:
A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
Abstract:
A storage device includes; an interface receiving data and a corresponding LBA from a host, wherein the data includes at least one of first data having a stream ID and second data lacking a stream ID, a nonvolatile memory (NVM) device including at least one nonvolatile memory configured to store the data, and a LBA predictor configured to provide a predicted stream ID for the second data using a neural network model operating in response to at least one feature associated with LBA values received by the storage device from the host, wherein the first data is stored in the NVM device using the stream ID, and the data is stored in the NVM device using the predicted stream ID.
Abstract:
Disclosed is a portable communication device, including a display, at least one microphone, a memory, and a processor operably connected to the display, the at least one microphone and the memory, wherein the processor is configured to display guide information, via the display, in response to a user input, the guide information including a first display object related to guide a user voice input for generation of a new voice command and a second display object related to at least one application executed by the new voice command via the portable communication device, receive audio data corresponding to the first display object from a user through the at least one microphone, generate the new voice command corresponding to the audio data, and store, in the memory, the new voice command corresponding to the received audio data and mapping information indicating that the new voice command and the at least one application are mapped.
Abstract:
Disclosed is an electronic device includes a display, a communication circuit, a processor, and a memory. The memory stores instructions that cause the processor to receive a natural language input from a user, to transmit at least a portion of the natural language input to an external server, to display a first message based on the natural language input and a first indication indicating the user, to receive a first response from the external server, to display a second indication indicating a first engine and a second message based on the first response, to receive a second response from the external server, and to display a third indication indicating a second engine and a third message based on the second response. The first response is generated by the first engine based on the natural language input, and the second response is generated by the second engine based on the natural language input.
Abstract:
A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.